Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and ...
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients....
近年来,GLP-1 受体激动剂(Glucagon-like peptide-1 receptor agonists, GLP-1RA)因在控制血糖和减重方面的良好疗效受到广泛关注。 11月28日,在波士顿举行的肥胖症和NASH药物开发峰会上,Sagimet公司在报告中分享了一项关于NASH小鼠模型的研究结果。该结果表明,将一种与其药物denifanstat类似的新型脂肪酸合成酶(FASN)抑...
Glucagon-like peptide 1GLP-1Eating disordersMeta-analysisGlucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating ...
The unique glycine residue at the DPP-IV cleavage site renders the protein unrecognizable by DPP-IV and prolongs the half-life of the peptide. Thus, the exendin-4 backbone has been utilized in the creation of longer-acting synthetic GLP-1R agonists.Figure adapted from Glotfelty et al. [5]....
The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital component of the G protein-coupled receptor (GPCR) family and is found primarily on the surfaces of various cell types within the human body. This receptor specifically interacts w
Glucagon-like peptide 1 (GLP-1) is an intestine-derived insulinotropic hormone that stimulates glucose-dependent insulin production and secretion from pancreatic beta-cells. Other recognized actions of GLP-1 are to suppress glucagon secretion and hepatic glucose output, delay gastric emptying, reduce fo...
Obesity has become a global public health issue, with the number of overweight/obese individuals increasing annually. However, weight loss faces various difficulties and challenges. Incretin medications, represented by glucagon-like peptide-1 (GLP-1), have brought new hope in the battle against obesi...
Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and inflammation — actions that could contribute to the reduction of cardiovascular events. Cardiovascular outcome trials (CVOTs) have demonstrated that GLP1R agonists reduce ...
Targher G. Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials.Metabolites. 2021;11.[PubMed][DOI][Cited in This Article:1][Cited by in Crossref: 65][Cited by in ...